Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps.
Details
Serval ID
serval:BIB_CC6C6C70B498
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps.
Journal
Current opinion in chemical biology
ISSN
1879-0402 (Electronic)
ISSN-L
1367-5931
Publication state
Published
Issued date
06/2009
Peer-reviewed
Oui
Volume
13
Number
3
Pages
338-344
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Publication Status: ppublish
Abstract
In this mini review, prodrugs are discussed with a focus on their pharmaceutical, pharmacokinetic, and pharmacodynamic objectives, as well as on the resulting therapeutic benefits. Carrier-linked prodrugs remain the most extensively investigated and receive due attention here with recent successes highlighted. A clear trend is apparent in modern prodrug research, namely the increased attention given to the knowledge-based design of bioprecursors, namely prodrugs devoid of a detachable promoiety. In most cases, such prodrugs are activated by in situ reduction, hence their designation as bioreductive prodrugs. This is a particularly active field in the design of more selective, small-molecule antitumor agents. New antimicrobial agents are also in the pipeline. In addition, biooxidative bioprecursors offer a promising strategy in specific cases, as illustrated by the successful antiaggregating agent clopidogrel.
Keywords
Chemistry, Pharmaceutical, Drug Delivery Systems, Humans, Prodrugs/pharmacokinetics, Prodrugs/pharmacology
Pubmed
Web of science
Create date
09/02/2010 16:50
Last modification date
17/02/2024 8:12